Barriers and Facilitators of Adherence to Mediterranean-Ketogenic and MCT-Supplemented Mediterranean Diets in Parkinson’s Disease: A Qualitative Secondary Analysis from a Random-Order Crossover Trial
Objective: To assess the barriers and facilitators of dietary adherence among people with Parkinson’s disease (PD) following an 8-week Mediterranean-ketogenic and 8-week MCT-supplemented Mediterranean diet.…Effect of Reaction Oriented Training on Postural Stability and Reaction Time in Parkinsons’s Disease
Objective: This study aimed to examine the effect of reaction-oriented training (ROT), a novel rehabilitation approach developed for people with Parkinson's disease (pwPD), on postural…Differential Motor Cortex Compensation in Parkinson’s Disease based on Putamen Neurodegeneration Laterality: Insights from EEG and [¹⁸F]FDOPA PET/CT
Objective: To investigate differences in motor cortex compensation across Parkinson’s disease (PD) patients with different putamen neurodegeneration laterality. Background: Abnormalities in the putamen–motor cortex (M1)…Modeling Levodopa Resistance in Parkinson’s Disease: A Novel Approach Targeting Locus Coeruleus Degeneration
Objective: To develop a Parkinson’s disease (PD) model replicating levodopa (LD) resistance by incorporating degeneration of both the substantia nigra (SN) and locus coeruleus (LC),…VQ-101, a CNS-Penetrant Small Molecule Allosteric Activator of Glucocerebrosidase (GCase), Demonstrates Favorable Tolerability and Sustained Activation of Lysosomal GCase in Individuals with Parkinson’s Disease
Objective: To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of VQ-101 in healthy volunteers (HVs), and individuals with Parkinson’s disease (PD) with and without GBA1…The Effect of Foslevodopa/Foscarbidopa Treatment on Nonmotor Symptom Burden in Advanced Parkinson’s Disease
Objective: To investigate the impact of foslevodopa/foscarbidopa (LDp/CDp) on nonmotor symptoms (NMS) in adults with advanced Parkinson’s disease (aPD). Background: LDp/CDp, a 24-hour per day…Inpatient Multimodal Intensive Care in Moderately Advanced Parkinson’s Disease: Role Of Medication Adjustment In Outcome Measures
Objective: In this study, we wish to determine whether medication changes play a major role in the improvements observed after in-patient multimodal intensive neurorehabilitation and…Opicapone improves end-of-dose neuropsychiatric fluctuations in patients with Parkinson’s disease
Objective: We aim to evaluate the efficacy of Opicapone (OPC) on end-of-dose neuropsychiatric fluctuations, the most frequent and severe non-motor fluctuations (NMF) in Parkinson’s disease (PD) patients [1].…Evaluation of the Pharmacodynamic Effects of BIIB122/DNL151 in Participants with LRRK2 mutation-driven Parkinson’s disease (BEACON Study)
Objective: To characterize the biomarker effects of BIIB122/DNL151 in participants with LRRK2 pathogenic mutations diagnosed with Parkinson’s disease (LRRK2-PD). Background: BIIB122/DNL151 is a CNS-penetrant small…Plasma Protein Profiles Reveal Distinct Molecular Signatures in Parkinson’s Disease and Multiple System Atrophy
Objective: We aimed to identify distinct plasma proteins in patients with Parkinson’s disease (PD) and multiple system atrophy (MSA) and evaluate their associations with disease…
- « Previous Page
- 1
- …
- 78
- 79
- 80
- 81
- 82
- …
- 436
- Next Page »